US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Asco 2020 – Enhertu impresses, but can it live up to high hopes?
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
Gilead opts not to buy Arcus
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
EAN 2020 – Atara’s multiple sclerosis plan slowly takes shape
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
J&J holds its own on sales per employee
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
Big pharma heads towards important readouts
Clinical data are expected soon from Novo Nordisk, Bayer and Sanofi, while Roche and Gilead take aim at ulcerative colitis.
Asco 2020 – small-cell lung cancer and the role of CTLA-4
Astra and Merck & Co present mixed small-cell lung cancer data, while Innovent, Xencor, Alphamab and Alligator bang the drum for CTLA-4.
Asco 2020 – first-line lung cancer focus
The upcoming cancer meeting shows Roche and Bristol trying to catch up with Merck & Co, with some read-across to biotech.
